Structural and biochemical properties of fibroblast growth factor 23

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 4, 2005, Pages 313-318

  Yamashita, Takeyoshi ^a  

^a KIRIN BREWERY CO LTD   (Japan)

Author keywords

Biochemistry; ELISA; Fibroblast growth factor 19; Fibroblast growth factor 23; Structure

Indexed keywords

FIBROBLAST GROWTH FACTOR 23;

ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

EID: 29144500469     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2005.00288.x     Document Type: Article

References (38)

1. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8.
2. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-8.
3. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004;20:563-9.
4. Harmer NJ, Pellegrini L, Chirgadze D et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel feaures of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004;43:629-40.
5. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5.
6. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MG. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF23. Kidney Int 2001;60:2079-86.
7. Shimada T, Muto T, Urakawa I et al. Mutant FGF23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2001;143:3179-82.
8. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957-60.
9. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63.
10. Weber TJ, Liu S, Indridason OS et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003;18:1227-34.
11. Liu S, Guo R, Simpson LG, Xian ZS, Burnham CE, Quarles LD. Regulation of FGF23 expression but not degradation by phex. J Biol Chem 2003;278:37419-26.
12. Bai XY, Miao D, Goltzman D et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003;278:9843-9.
13. Shimada T, Urakawa I, Yamazaki Y et al. FGF23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004;314:409-14.
14. Larsson T, Marsell R, Shipani E et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha 1(I) collagen promotor exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004;145:3087-94.
15. Bai XY, Miao D, Li J et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004;145:5269-79.
16. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;13:561-8.
17. Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverseshypophosphatemia in Phex-deficient mice. Matrix Biol 2004;23:421-32.
18. Shimada T, Hasegawa H, Yamazaki Y et al. FGF23 is a potent regulator of the vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35.
19. Segawa H, Kawakami E, Kaneko I et al. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch 2003;446:585-92.
20. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 2004;65:1-14.
21. Fu L, John LM, Adams SH et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145:2594-603.
22. Riminucci M, Collins MT, Fedarko NS et al. FGF23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683-92.
23. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-9.
24. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004;44:250-6.
25. Imanishi Y, Inaba M, Nakatsuka K et al. FGF23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65:1943-6.
26. Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004;44:481-7.
27. Yamazaki Y. Elevated circulatory and expression level of fibroblast growth factor (FGF)-23 in hypophosphatemic mice. (Abstract) Bone 2003;32:S88.
28. Yamashita T. Involvement of FGF-23 in abnormal vitamin D and mineral metabolism associated with renal insufficiency (Abstract) J Am Soc Nephrol 2002;13:577A.
29. Kazama JJ Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients with secondary hyperparathyroidism (Abstract) J Am Soc Nephrol 2004;15:282A.
30. Takeuchi Y, Suzuki H, Ogura S et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004;89:3979-82.
31. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005;14:385-90.
32. Araya K. A mutation in FGF-23 gene enhances the processing of FGF-23 protein and causes tumoral calcinosis (Abstract) J Bone Miner Res 2004;19:S41.
33. Frishberg Y. Hyperostosis-hyperphosphatemia syndrome caused by mutations in GALNT3 and associated with augmented processing of FGF-23 (Abstract) J Am Soc Nephrol 2004;15:269A.
34. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005;90:1519-24.
35. Saito H, Maeda A, Ohtomo SI et al. Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005;280:2543-9.
36. Tebben PJ, Singh RJ, Clarke BL et al. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc. 2004;79:1508-13
37. Singh RJ, Kumar R. Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc 2003;78:826-9.
38. Yamashita H, Yamashita T, Miyamoto M et al. Fibroblast growth factor (FGF) -23 in patients with primary hyperparathyroidism. Eur J Endocrinol 2004;151:55-60.